Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

PHASE3CompletedINTERVENTIONAL
Enrollment

297

Participants

Timeline

Start Date

November 20, 2017

Primary Completion Date

February 14, 2019

Study Completion Date

February 14, 2019

Conditions
ADHD
Interventions
DRUG

Placebo

Placebo was administered once daily

DRUG

400mg SPN-812

400mg SPN-812 was administered once daily and compared to Placebo

DRUG

600mg SPN-812

600mg SPN-812 was administered once daily and compared to Placebo

Trial Locations (14)

29407

Carolina Clinical Trials, Inc., Charleston

30030

iResearch Atlanta, Decatur

32803

APG Research, LLC, Orlando

33155

Miami Clinical Research, Miami

33319

Innovative Clinical Research, Inc, Lauderhill

34201

Meridien Research at Florida Clinical Research Center, Bradenton

73103

IPS Research, Oklahoma City

73118

Paradigm Research Professionals, Oklahoma City

77006

Bayou City Research Corporation, Houston

77061

Discovery MM Services Inc. Houston, Houston

77702

Gadolin Research, LLC, Beaumont

80910

MCB Clinical Research Centers, LLC, Colorado Springs

84015

Ericksen Research & Development, Clinton

90807

Alliance for Wellness dba Alliance for Research, Long Beach

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT03247556 - Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD | Biotech Hunter | Biotech Hunter